Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Why now
Thesis: Binary Phase 3 readout looms for Kodiak Sciences
Catalyst to watch: Topline results on September 28, 2026
Main risk: Negative data could sharply devalue the stock
Why it matters
A pivotal Phase 3 readout is binary for the company and a sentiment input for retina biotech.
Details
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
Sources
- prnewswire · 2026-09-25 22:01 UTC